[Paper] survodutide MASH data is the most interesting hepatic readout in the class
Trying to settle this properly because the thread from last year went in circles.
The claim: MASH matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 3 months without either producing anything.
What would actually settle it is 9 people measuring the same thing the same way. I have started; my numbers are below. They lean one way but not strongly enough for me to declare victory.
If you have data, post the data. If you have an opinion, flair it as an opinion.
best — the order this archive was captured in
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
Small correction: the trial was 6 weeks, not 31. Does not change your point but people will quote it.
Tracking number removed. It identifies both ends of a shipment.
MASH claims need the trial and the biopsy endpoint
Not convinced. The evidence does not support that reading.
MASH claims need the trial and the biopsy endpoint
I am going to push back on this slightly.
the safety profile is not just tirzepatide amplified
glucagon injection is a different vector than GLP-1
phase 20 data is interesting, phase 12 will be different
MASH claims need the trial and the biopsy endpoint
- 1MASH claims need the trial and the biopsy endpoint8 comments in this branch · started by u/julia_mensa